Nautilus Biotechnology, Inc. (NAUT) - Comprehensive Stock Analysis & Investment Research
Deep dive into Nautilus Biotechnology, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.
Nautilus Biotechnology, Inc. Investment Summary
When evaluating whether Nautilus Biotechnology, Inc. (NAUT) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.
Company Profile
Nautilus Biotechnology, Inc. (NAUT) operates within the Industrial Applications and Services sector, specifically in the Laboratory Analytical Instruments industry. The company employs approximately 170 people. With a market capitalization of $307 million, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.
Financial Performance Analysis
Our comprehensive financial analysis covers Nautilus Biotechnology, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...
AI Price Predictions
Get AI-powered 7-day, 30-day and 90-day price forecasts for Nautilus Biotechnology, Inc. along with confidence scores and detailed analysis...
Investment Considerations
Expert analysis of whether Nautilus Biotechnology, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...
Corporate Identity
Nautilus Biotechnology, Inc. (Stock Symbol: NAUT) is a prominent company operating within the Industrial Applications and Services sector, with a specific focus on the Laboratory Analytical Instruments industry. The company's shares are publicly traded on the Nasdaq exchange.
Leadership & Workforce
Detailed information about Nautilus Biotechnology, Inc.'s leadership team, workforce size, and organizational structure...
Market Classification
Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Nautilus Biotechnology, Inc....
Sector & Industry Analysis
In-depth sector dynamics and industry context for Nautilus Biotechnology, Inc....
Revenue & Growth Analysis
Nautilus Biotechnology, Inc. generates annual revenues of $707 million , representing an emerging company in its growth phase.
Profitability Metrics
Net profit margin, gross margin, and operating margin analysis for Nautilus Biotechnology, Inc....
Market Valuation
P/E ratio, price-to-book, and valuation multiples for Nautilus Biotechnology, Inc....
Return Metrics
Return on equity (ROE), return on assets (ROA), and capital efficiency for Nautilus Biotechnology, Inc....
Strategic Market Position
Nautilus Biotechnology, Inc. strategically competes in the highly dynamic Laboratory Analytical Instruments marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.
Industry Competitive Landscape
Nautilus Biotechnology, Inc. competes within the Industrial Applications and Services sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.
Operational Efficiency
The company currently shows negative free cash flow of $-48 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.
Margin & Pricing Power Analysis
The company maintains a 42.3% gross margin indicating healthy pricing power relative to direct production costs. This margin level suggests the company has successfully differentiated its products or services, allowing it to command prices meaningfully above input costs. Maintaining these margins requires ongoing investment in brand, technology, or other differentiating factors.
Operating margin of 7.5% demonstrates how efficiently the company converts revenues into operating profits after accounting for all operating expenses including research and development, sales and marketing, and general administrative costs. Operating margin compression relative to gross margin suggests high operating expenses that may warrant efficiency improvements or reflect necessary growth investments.
Asset Utilization Efficiency
Asset turnover ratio of 1.59x indicates exceptional efficiency in utilizing company assets to generate revenue. High asset turnover is characteristic of retail, distribution, or service businesses that operate with relatively lean asset bases. This efficiency translates to higher returns on invested capital when combined with reasonable margins.
Financial Strength & Leverage
Current ratio of 51.05 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.